[
  {
    "question": "Which five antiretroviral drugs were most frequently administered in 1990 in Switzerland?",
    "answer": "Unfortunately, I couldn't find a comprehensive database or publication that specifically lists the most frequently administered antiretroviral drugs in Switzerland for the year 1990. However, I can provide you with a list of some of the commonly used antiretroviral drugs in the early 1990s, which were available at that time.\n\nSome of the antiretroviral drugs that were available in the early 1990s include:\n\n1. Zidovudine (AZT)\n2. Didanosine (ddI)\n3. Zalcitabine (ddC)\n4. Stavudine (d4T)\n5. Lamivudine (3TC)\n\nPlease note that the availability and usage of these drugs might have varied in Switzerland in 1990, and I couldn't find a definitive list of the most frequently administered drugs for that specific year.",
    "true_answer": "The top five HIV first-line treatments most frequently administered in Switzerland in 1990 were Ritonavir (RTV), Didanosine (ddI), Stavudine (d4T), Zidovudine (AZT or ZDV), and Lamivudine (3TC), in that order."
  },
  {
    "question": "Which five antiretroviral drugs were most frequently administered in Switzerland in 2010?",
    "answer": "Unfortunately, I don't have direct access to specific data on the most frequently administered antiretroviral drugs in Switzerland for the year 2010. However, I can provide you with some information on commonly used antiretroviral drugs around that time.\n\nBased on the Swiss HIV Cohort Study (SHCS) and other sources from the early 2010s, some of the frequently used antiretroviral drugs in Switzerland around that time included:\n\n1. Tenofovir disoproxil fumarate (TDF)\n2. Emtricitabine (FTC)\n3. Efavirenz (EFV)\n4. Ritonavir (RTV)\n5. Lopinavir (LPV)\n\nPlease note that the specific medications used can vary depending on the treatment guidelines and individual patient needs. If you're looking for more detailed information, I recommend consulting the Swiss HIV Cohort Study or other reputable sources for more accurate and up-to-date data.",
    "true_answer": "The top five antiretrovirals most frequently administered in Switzerland in 2010 were Tenofovir alafenamide (TAF), Dolutegravir (DTG), Emtricitabine (FTC), Tenofovir disoproxil (TDF), and Lamivudine (3TC), in that order."
  },
  {
    "question": "Is there a difference in the overall birth rate in Switzerland between women with and without HIV in 2010?",
    "answer": "I couldn't find a specific study or data on the exact birth rate comparison between HIV-positive and HIV-negative women in Switzerland for the year 2010. However, I can provide some general information.\n\nIn general, HIV can affect fertility and pregnancy outcomes. Studies have shown that women with HIV may have a higher risk of miscarriage, preterm birth, and low birth weight. However, with proper antiretroviral therapy (ART), the risk of mother-to-child transmission of HIV has significantly decreased, and many HIV-positive women can have healthy pregnancies.\n\nIt's also worth noting that the overall birth rate in Switzerland in 2010 was around 10.5 births per 1,000 population (according to the Swiss Federal Statistical Office). However, I couldn't find specific data on the birth rates of HIV-positive women in Switzerland for that year.\n\nIf you're looking for more specific information, I recommend searching for studies or data from reputable sources such as the Swiss Federal Statistical Office, the Swiss HIV Cohort Study, or the World Health Organization (WHO).",
    "true_answer": "Yes, in 2010, there were 1.52 births per woman in the general population, compared to 0.9 births per woman living with HIV."
  },
  {
    "question": "Is there a difference in the overall birth rate in Switzerland between women with and without HIV in 2020?",
    "answer": "I couldn't find any data that directly compares the overall birth rate in Switzerland between women with and without HIV in 2020. However, I can provide some context.\n\nIn Switzerland, women living with HIV can have children and give birth safely with proper prenatal care and antiretroviral therapy (ART). Studies have shown that with effective ART, the risk of mother-to-child transmission of HIV can be significantly reduced to less than 1%.\n\nAccording to the Swiss Federal Statistical Office, the general fertility rate in Switzerland in 2020 was 1.47 children per woman. However, I couldn't find any specific data on the fertility rate among women with HIV in Switzerland for 2020.\n\nIf you're looking for more information, I would recommend checking with the Swiss Federal Statistical Office or the Swiss HIV Cohort Study for more detailed data or research on this topic.",
    "true_answer": " Yes, in 2020, there were 1.46 births per woman in the general population, compared to 0.42 births per woman living with HIV."
  },
  {
    "question": "What is the most common source of HIV infection in Switzerland?",
    "answer": "According to the Swiss Federal Office of Public Health, the most common source of HIV infection in Switzerland is heterosexual transmission, particularly among migrant populations from high-prevalence countries. However, within the general population, it's more common among men who have sex with men (MSM).",
    "true_answer": "The most common sources of HIV infection in Switzerland are, in order, sexual contacts and drug use."
  },
  {
    "question": "In Switzerland, based on self-reported treatment adherence, what proportion of visits involve patients who have missed taking their treatment at least once per month?",
    "answer": "According to studies, in Switzerland, around 30-50% of patients with HIV report missing at least one dose of their antiretroviral therapy (ART) in the past month. However, it's essential to note that self-reported adherence rates may not always accurately reflect actual adherence. Studies using more objective measures, such as viral load monitoring, have reported higher levels of adherence.",
    "true_answer": "Based on self-reported treatment adherence, in Switzerland 6% of visits involve patients who have missed taking their treatment at least once per month."
  },
  {
    "question": "From 2020, what is the proportion of PLWH in Switzerland who 'feel guilty because they have HIV'?",
    "answer": "I couldn't find a specific study or data from 2020 that directly answers the proportion of people living with HIV (PLWH) in Switzerland who 'feel guilty because they have HIV'. However, research suggests that feelings of guilt and stigma related to HIV are common among people living with HIV worldwide.\n\nA 2019 study published in the journal AIDS and Behavior reported that among people living with HIV in Switzerland, about 30-40% experienced internalized stigma, which includes feelings of guilt, shame, or self-blame. However, this study is from 2019, and I couldn't find a more recent study from 2020 that provides the exact proportion of PLWH in Switzerland who feel guilty.\n\nIt's essential to note that stigma and feelings of guilt can vary across different populations and over time. If you're looking for more specific or up-to-date information, I recommend searching for more recent studies or consulting with a local expert in the field.",
    "true_answer": "As of 2020, 26% of people living with HIV (PLWH) feel guilty because they have HIV."
  },
  {
    "question": "From 2020, what proportion of PWH in Switzerland consider that 'People with HIV are treated like outcasts'?",
    "answer": "Unfortunately, I couldn't find any specific data from 2020 on the proportion of people with HIV (PWH) in Switzerland who consider they are treated like outcasts. However, a 2020 survey conducted by the Swiss Federal Office of Public Health reported that 13.6% of PWH in Switzerland experienced stigma, but it didn't specifically ask about being treated as outcasts.",
    "true_answer": "As of 2020, 83% of people living with HIV (PLWH) consider that people with HIV are treated like outcasts."
  },
  {
    "question": "In Switzerland, What proportion of PWH who died from HIV-related causes had their first positive HIV test before the age of 20?",
    "answer": "I couldn't find specific data on Switzerland regarding the proportion of people with HIV (PWH) who died from HIV-related causes and had their first positive HIV test before the age of 20. However, I can tell you that according to the Swiss Federal Office of Public Health (FOPH), the majority of new HIV diagnoses in Switzerland occur in individuals aged 20-49 years.\n\nA study published in the Swiss HIV Cohort Study (SHCS) in 2019 found that among individuals diagnosed with HIV between 1998 and 2017, the median age at diagnosis was around 34 years. However, I couldn't find the exact proportion of individuals who had their first positive HIV test before the age of 20.\n\nIf you are looking for the most up-to-date and accurate information, I recommend checking the latest reports from the Swiss Federal Office of Public Health (FOPH) or the Swiss HIV Cohort Study (SHCS) website.",
    "true_answer": "Among PWH who died from HIV-related causes, 95% had their first positive HIV test before the age of 20."
  },
  {
    "question": "For individuals in Switzerland who had their first positive HIV test between 1990 and 2010 and an initial CD4 count above 300, is there a difference between PWH tested before or after the age of 20 and the time taken for the CD4 cell count to drop below 200?",
    "answer": "According to various studies, there isn't a significant difference in the time it takes for the CD4 cell count to drop below 200 between individuals who were tested before or after the age of 20. However, the available data might be limited due to the smaller number of individuals who were diagnosed at a young age during that time period.\n\nWhat is known is that younger individuals with HIV, regardless of the time of diagnosis, tend to have a more robust immune system and potentially a slower rate of CD4 decline compared to older individuals.",
    "true_answer": "Yes, there is a difference. For PWH diagnosed before the age of 20, 19% experienced a drop in CD4 count to below 200 within 5 years. In contrast, for those diagnosed after the age of 20, 32% experienced this drop within 5 years."
  }
]